Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-125437
Filing Date
2024-11-12
Accepted
2024-11-12 16:15:48
Documents
62
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q nmra-20240930.htm   iXBRL 10-Q 2668728
2 EX-31.1 nmra-ex31_1.htm EX-31.1 17472
3 EX-31.2 nmra-ex31_2.htm EX-31.2 17465
4 EX-32.1 nmra-ex32_1.htm EX-32.1 10289
5 EX-32.2 nmra-ex32_2.htm EX-32.2 10249
6 GRAPHIC img235852261_0.jpg GRAPHIC 720289
7 GRAPHIC img235852261_1.jpg GRAPHIC 16758
  Complete submission text file 0000950170-24-125437.txt   10407200

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nmra-20240930.xsd EX-101.SCH 1186692
65 EXTRACTED XBRL INSTANCE DOCUMENT nmra-20240930_htm.xml XML 1329792
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41802 | Film No.: 241448407
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)